Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus

References

1. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13:48–64 [View Article] [PubMed]
   [Google Scholar]
2. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016; 64:S4–S16 [View Article] [PubMed]
   [Google Scholar]
3. World Health Organisation Global hepatitis report; 2017 https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
4. Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3:383–403
   [Google Scholar]
5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249 [View Article] [PubMed]
   [Google Scholar]
6. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016; 388:1081–1088 [View Article] [PubMed]
   [Google Scholar]
7. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230–239 [View Article] [PubMed]
   [Google Scholar]
8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104–1108 [View Article] [PubMed]
   [Google Scholar]
9. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750–1758 [View Article] [PubMed]
   [Google Scholar]
10. Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep 2014; 13:235–244 [View Article] [PubMed]
    [Google Scholar]
11. Lim SG, Baumert TF, Boni C, Gane E, Levrero M et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol 2023; 20:238–253 [View Article] [PubMed]
    [Google Scholar]
12. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019; 4:545–558 [View Article] [PubMed]
    [Google Scholar]
13. Flores R, Owens RA, Taylor J. Pathogenesis by subviral agents: viroids and hepatitis delta virus. Curr Opin Virol 2016; 17:87–94 [View Article] [PubMed]
    [Google Scholar]
14. Taylor J, Pelchat M. Origin of hepatitis delta virus. Future Microbiol 2010; 5:393–402 [View Article] [PubMed]
    [Google Scholar]
15. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020; 73:523–532 [View Article] [PubMed]
    [Google Scholar]
16. Thiyagarajah K, Basic M, Hildt E. Cellular factors involved in the hepatitis D virus life cycle. Viruses 2023; 15:1687 [View Article] [PubMed]
    [Google Scholar]
17. McNaughton AL, D’Arienzo V, Ansari MA, Lumley SF, Littlejohn M et al. Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood. Gastroenterology 2019; 156:384–399 [View Article] [PubMed]
    [Google Scholar]
18. Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020; 17:618–634 [View Article] [PubMed]
    [Google Scholar]
19. Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K et al. Analysis of hepatitis B virus haplotype diversity detects striking sequence conservation across genotypes and chronic disease phase. Hepatology 2021; 73:1652–1670 [View Article] [PubMed]
    [Google Scholar]
20. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254–265 [View Article] [PubMed]
    [Google Scholar]
21. Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E et al. Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection. Lancet Gastroenterol Hepatol 2024; 9:383–392 [View Article] [PubMed]
    [Google Scholar]
22. Zheng Y, Wang M, Yin J, Duan Y, Wu C et al. Hepatitis B virus RNAs co-opt ELAVL1 for stabilization and CRM1-dependent nuclear export. PLoS Pathog 2024; 20:e1011999 [View Article] [PubMed]
    [Google Scholar]
23. Mendenhall MA, Hong X, Hu J. Hepatitis B virus capsid: the core in productive entry and covalently closed circular DNA formation. Viruses 2023; 15:642 [View Article] [PubMed]
    [Google Scholar]
24. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an In Vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol 2018; 92:e02007-17 [View Article] [PubMed]
    [Google Scholar]
25. Kojima R, Nakamoto S, Kogure T, Ma Y, Ogawa K et al. Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma. World J Virol 2023; 12:209–220 [View Article] [PubMed]
    [Google Scholar]
26. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021; 74:283–292 [View Article] [PubMed]
    [Google Scholar]
27. Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018; 67:2045–2053 [View Article] [PubMed]
    [Google Scholar]
28. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2022; 22:19–32 [View Article] [PubMed]
    [Google Scholar]
29. Kosinska AD, Festag J, Mück-Häusl M, Festag MM, Asen T et al. Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection. Vaccines 2021; 9:841 [View Article] [PubMed]
    [Google Scholar]
30. Pearlman B. Hepatitis delta infection: a clinical review. Semin Liver Dis 2023; 43:293–304 [View Article] [PubMed]
    [Google Scholar]
31. Bassit L, Amblard F, Patel D, Biteau N, Chen Z et al. The premise of capsid assembly modulators towards eliminating HBV persistence. Expert Opin Drug Discov 2023; 18:1031–1041 [View Article] [PubMed]
    [Google Scholar]
32. Amblard F, Boucle S, Bassit L, Cox B, Sari O et al. Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses In Vitro and in humanized mice. Antimicrob Agents Chemother 2020; 64:e01701-19 [View Article] [PubMed]
    [Google Scholar]
33. Pérez-Vargas J, Pereira de Oliveira R, Jacquet S, Pontier D, Cosset F-L et al. HDV-Like viruses. Viruses 2021; 13:1207 [View Article] [PubMed]
    [Google Scholar]
34. Hesterman MC, Furrer SV, Fallon BS, Weller ML. Analysis of hepatitis D virus in minor salivary gland of Sjögren’s disease. J Dent Res 2023; 102:1272–1279 [View Article] [PubMed]
    [Google Scholar]
35. Rizzetto M. Chronic hepatitis D; at a standstill?. Dig Dis 2016; 34:303–307 [View Article] [PubMed]
    [Google Scholar]
36. Blumberg BS, Alter HJ, Visnich S. A "New" antigen in Leukemia Sera. JAMA 1965; 191:541–546 [View Article] [PubMed]
    [Google Scholar]